🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very excited to share that our paper is online now in [Molecular Cancer] on pan-cancer characterization of CD40 and immune checkpoint blockade therapy (free access!). molecular-cancer.biomedcentral.com/articles/10.11… Vanderbilt School of Medicine Basic Sciences BMC Dermal Cell News

Delighted to share our new paper in npj Precision Oncology npj Journals @VUMC_Cancer Vanderbilt School of Medicine Basic Sciences. Spatially organized immune-malignant cell interaction reveals the mechanism of acquired resistance to BRAF/MEK-targeted therapies in metastatic melanoma. nature.com/articles/s4169…

Pleased to share our story Behind The Paper Nature Portfolio npj Journals. This study was a true collaborative effort!!! @VUMC_Cancer Vanderbilt School of Medicine Basic Sciences cancercommunity.nature.com/posts/mechanis…

Glad to share our Research Snapshot: Vanderbilt team discovers potential explanation for treatment resistance in skin cancer news.vanderbilt.edu/2022/02/28/res…

Excited to share that our CD40 pan-cancer analysis paper gets highlighted! Vanderbilt School of Medicine Basic Sciences medschool.vanderbilt.edu/basic-sciences…

Today is International Day for Immunology! It's a perfect time to reflect on it and how it has impacted so many areas. An amazing interdisciplinary field, colleagues, and trainees. Immunology is everywhere!

Deeply honored to receive the AAI Early Career Faculty Travel Grant #AAI2022 The American Association of Immunologists (AAI) Vanderbilt School of Medicine Basic Sciences @VUMC_VCI

As a new PI, I am more than grateful and excited to receive the Melanoma Research Grant for my lab from The Harry J. LIoyd Foundation! Sincere thanks to my mentor Dr. Ann Richmond and collaborators Drs. Douglas Johnson, Jeff Rathmell and @mallal_simon!@VUBasicSciences

A new review by Chi Yan, Ph.D. presents the current mechanistic understanding, efficacy, and safety profiles of P13K, MAPK, and immune checkpoint inhibitors—treatments for malignant melanoma and metastatic triple-negative breast cancer. mdpi.com/1422-0067/23/1…

I’m thrilled! This Phase II clinical trial of rigosertib (a RAS-pathway inhibitor) for ICB-resistant melanoma at Vanderbilt University, is a home-grown, bench to bedside study, and our lab proposed parallel correlative biomarker and mechanism discovery studies.Vanderbilt School of Medicine Basic Sciences

Check out our paper just published in Molecular Cancer (Impact factor = 41.4), in which we show that CXCR2 expression during melanoma tumorigenesis controls transcriptional programs that facilitate tumor growth (doi.org/10.1186/s12943…)Vanderbilt School of Medicine Basic Sciences Vanderbilt School of Medicine

In a recent Molec Cancer paper, Kensey Bergdorf-Smith, PhD, Jinming Yang & Chi Yan, Ph.D. (of the Ann Richmond lab) provide novel mechanistic insight into Cxcr2 expression/activity in melanoma tumor progenitor cells. Learn more in an interview with the authors! medschool.vanderbilt.edu/basic-sciences… Vanderbilt Pharmacology

This review on CD40 from the Ann Richmond lab is a must read 👇 “This is an outstanding review—well-written, comprehensive and beautifully illustrated. It was accepted without revision,” CGFR Editor-in-Chief. doi.org/10.1016/j.cyto… Chi Yan, Ph.D. Vanderbilt Pharmacology

Teaching is challenging, but the rewards are gratifying. I am immensely proud of our undergraduate researcher Yang Zhou, who was awarded Highest Honors and the Best Undergraduate Researcher Award in the Biological Sciences at Vanderbilt! Vanderbilt School of Medicine Basic Sciences doi.org/10.1016/j.cyto…